Interim report January

Strong sales growth in Asia and strengthened operating income
Second quarter
Group, including discontinuing operations

  · Sales growth was 20 percent in local currency. Sales were the highest ever
for a single quarter and amounted to SEK 109 (88) million, corresponding to an
increase of 25 percent in SEK.
  · Sales growth within Fertility was 21 percent in local currency and 25
percent in SEK and was generated primarily by continued strong sales growth in
Asia. Sales growth within Transplantation was 18 percent in local currency and
25 percent in SEK.
  · Operating income (EBIT) amounted to SEK 17 (13) million, corresponding to an
increase of 32 percent. The operating margin was 15 (14) percent. Income before
tax amounted to SEK 18 (15) million. Net income amounted to SEK 13 (10) million,
which gave earnings per share of SEK 0.67 (0.51).
  · Dividend of SEK 0.60 (0.60) per share, in total SEK 11,737,661 (11,735,914).
  · Thomas Axelsson appointed as CEO of Vitrolife.
  · Vitrolife entered into an agreement to acquire Cryo Management Ltd, one of
the world’s leading players within time-lapse for IVF, based in Hungary.
  · Application for sales approval of STEEN Solution™ in the USA was submitted
to the US Food and Drug Administration, FDA, after the end of the reporting
period.

First half year
Group, including discontinuing operations

  · Sales growth was 16 percent in local currency. Sales amounted to SEK 209
(176) million, corresponding to an increase of 19 percent in SEK. Sales growth
within Fertility was 15 percent in local currency and 18 percent in SEK. Sales
growth within Transplantation was 17 percent in local currency and 24 percent in
SEK.
  · Operating income (EBIT) amounted to SEK 32 (23) million, corresponding to an
increase of 40 percent. The operating margin was 15 (13) percent. Income before
tax amounted to SEK 32 (27) million. Net income amounted to SEK 23 (19) million,
which gave earnings per share of SEK 1.15 (0.96).
  · The Board decided to begin preparations for a spin-off of the
transplantation business. It is planned that the spin-off will take place during
the second half of 2012 through distribution of the shares in the subsidiary
Xvivo Perfusion AB in accordance with “Lex Asea”.

July 13, 2012

Gothenburg, Sweden

VITROLIFE AB (publ)

Thomas Axelsson

CEO
Queries should be addressed to:

Thomas Axelsson, CEO, phone 46 31 721 80 01

Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on July
13, 2012 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global
biotechnology/medical device Group that works in the areas of Fertility and
Transplantation. The Fertility (http://www.vitrolife.com/en/Fertility/) product
area works with nutrient solutions (media), cryopreservation products and
advanced consumable instruments such as needles and pipettes, for the treatment
of human infertility. Work is also carried out to enable the use and handling of
stem cells for therapeutic purposes. The
Transplantation (http://www.xvivoperfusion.com/transplantation/) product area
works with solutions and systems for assessing and preserving organs outside the
body, so as to be able to select usable organs and keep them in optimal
condition pending transplantation.

Vitrolife (http://www.vitrolife.com/en/Corporate/) today has approximately 220
employees and its products are sold in almost 90 markets. The company is
headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China and Japan. The Vitrolife
share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on
NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Interim report January - June 2012

Anhänge
